scholarly journals Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report

2017 ◽  
Vol 28 (1) ◽  
pp. 107-109 ◽  
Author(s):  
Orkun Aydin ◽  
Pınar Ünal-Aydin
Nutrients ◽  
2018 ◽  
Vol 10 (5) ◽  
pp. 548 ◽  
Author(s):  
Hanna Karakula-Juchnowicz ◽  
Mirosława Gałęcka ◽  
Joanna Rog ◽  
Anna Bartnicka ◽  
Zuzanna Łukaszewicz ◽  
...  

2016 ◽  
Vol 36 (6) ◽  
pp. 710-715 ◽  
Author(s):  
Roberto Lewis-Fernández ◽  
Peter Lam ◽  
Susan Lucak ◽  
Hanga Galfalvy ◽  
Elizabeth Jackson ◽  
...  

2004 ◽  
Vol 34 (5) ◽  
pp. 777-785 ◽  
Author(s):  
P. B. MITCHELL ◽  
T. SLADE ◽  
G. ANDREWS

Background. There have been few large-scale epidemiological studies which have examined the prevalence of bipolar disorder. The authors report 12-month prevalence data for DSM-IV bipolar disorder from the Australian National Survey of Mental Health and Well-Being.Method. The broad methodology of the Australian National Survey has been described previously. Ten thousand, six hundred and forty-one people participated. The 12-month prevalence of euphoric bipolar disorder (I and II) – similar to the euphoric-grandiose syndrome of Kessler and co-workers – was determined. Those so identified were compared with subjects with major depressive disorder and the rest of the sample, on rates of co-morbidity with anxiety and substance use disorders as well as demographic features and measures of disability and service utilization. Polychotomous logistic regression was used to study the relationship between the three samples and these dependent variables.Results. There was a 12-month prevalence of 0·5% for bipolar disorder. Compared with subjects with major depressive disorder, those with bipolar disorder were distinguished by a more equal gender ratio; a greater likelihood of being widowed, separated or divorced; higher rates of drug abuse or dependence; greater disability as measured by days out of role; increased rates of treatment with medicines; and higher lifetime rates of suicide attempts.Conclusions. This large national survey highlights the marked functional impairment caused by bipolar disorder, even when compared with major depressive disorder.


2016 ◽  
Vol 33 (3) ◽  
pp. 175-178 ◽  
Author(s):  
M. Osman ◽  
M. D. McCauley

IntroductionMirtazapine is indicated in the treatment of major depressive disorder particularly in selective serotonin re-uptake inhibitors resistance. Its effect on hair loss is rare with no previous documented effect on hair colour.MethodReview of relevant literature and description of a case report of a 54-year-old male patient who developed alopecia and hair discoloration after initiation of mirtazapine treatment.ResultsUpon cessation of mirtazapine treatment full restoration of hair colour and regrowth of hair was attained within 10 weeks.DiscussionThere was clear temporal relationship between experiencing hair loss and commencing mirtazapine treatment. No other more likely medical reason to explain such experience was established. A noticeable restoration of the hair colour occurred following mirtazapine cessation.ConclusionMirtazapine is associated with hair discoloration and hair loss. The possibility of such distressing adverse effects needs to be conveyed to patients by clinicians and to be further explored by researchers.


2014 ◽  
Vol 75 (12) ◽  
pp. e23-e26 ◽  
Author(s):  
Souhel Najjar ◽  
Daniel M. Pearlman ◽  
Scott Hirsch ◽  
Kent Friedman ◽  
John Strange ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document